All In Biotech

Drug Trial Radar · NCT01511744

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

A Randomised, Controlled Phase IV Clinical Trial With an Inactivated Influenza Vaccine(Split Virion)

Last checked: Nov 20, 2026Latest source record: Aug 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,000

Actual

Start

Nov 2011

Primary completion

Nov 2011

Study completion Mar 2012

Sponsor

Sponsor type
Industry
First posted
Jan 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 3 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Influenza vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml) of Hualan Biological Bacterin Co., Ltd (The subsidiary of Hualan Biological Engineering INC.) is applicable to the influenza immunity of age 3 and older population. Phase III clinical study was conducted in Jintan City, Jiangsu Province in May, 2006. Trial results showed that this vaccine had good safety and immunogenicity. Hualan Bio Influenza Vaccine obtained its production approval(China Drug Approval No.: S20083016) for marketing on April 3rd, 2008. In order to monitor and evaluate the safety and protective effect against influenza administered on age 3 and older population, therefore we conduct the phase IV clinical trial of the licensed Influenza Vaccine (split virion), Inactivated (15ug HA/subtype/0.5ml).

Conditions

  • Human Influenza

Interventions

  • Inactivated influenza split vaccineBiological

    3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety studyTime frame: 28days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Province Center for Disease Preventionand Control

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.